Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adagio Medical HoldingsADGM -5.87%7 Debt-to-EBITDA is -1.14 as of Jun. 2026. GuruFocus rates ADGM with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 473 Medical Devices & Instruments companies, Adagio Medical Holdings ranks worse than 211416.28% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Adagio Medical Holdings's Debt-to-EBITDA or its related term are showing as below:
ADGM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.12 Med: -1.03 Max: -0.43
Current: -1.12
During the past 5 years, the highest Debt-to-EBITDA Ratio of Adagio Medical Holdings was -0.43. The lowest was -1.12. And the median was -1.03.
ADGM's Debt-to-EBITDA is ranked worse than 100% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs ADGM: -1.12
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Adagio Medical Holdings Debt-to-EBITDA Related Terms
Adagio Medical Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADGM vs NXL, ICCM, ALRTF: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Adagio Medical Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagio Medical Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adagio Medical Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adagio Medical Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Adagio Medical Holdings (ADGM) has a Debt-to-EBITDA of -1.14 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adagio Medical Holdings. According to the industry distribution chart, Adagio Medical Holdings ranks #999999 out of 473 companies in the Medical Devices & Instruments industry.
Is Adagio Medical Holdings' Debt-to-EBITDA too high?
Adagio Medical Holdings' current Debt-to-EBITDA is -1.14. Based on the distribution chart, Adagio Medical Holdings ranks #999999 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Adagio Medical Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Adagio Medical Holdings' Debt-to-EBITDA compare to NXL and ICCM?
According to the Medical Devices & Instruments industry distribution chart, Adagio Medical Holdings ranks #999999 out of 473 companies for Debt-to-EBITDA. This places Adagio Medical Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adagio Medical Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adagio Medical Holdings's current Debt-to-EBITDA is -1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagio Medical Holdings stock overvalued right now?
Adagio Medical Holdings (ADGM) has a current Debt-to-EBITDA of -1.14. The current Debt-to-EBITDA is -1.14. Adagio Medical Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Adagio Medical Holdings (ADGM), the current Debt-to-EBITDA is -1.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
7GF Score
Get the complete analysis for ADGM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADGM has been successfully added to your 
